{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:14:19Z","timestamp":1790820859409,"version":"4.1.0"},"reference-count":71,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T00:00:00Z","timestamp":1713744000000},"content-version":"vor","delay-in-days":418,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100006451","name":"Hospices Civils de Lyon","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006451","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.cmi.2022.10.030","type":"journal-article","created":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T22:26:17Z","timestamp":1667514377000},"page":"332-337","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["B-cell malignancies and COVID-19: a narrative review"],"prefix":"10.1016","volume":"29","author":[{"given":"David","family":"Luque-Paz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Sesques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florent","family":"Wallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Bachy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Ader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2022.10.030_bib1","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2119893119","article-title":"COVID-19 therapeutics: challenges and directions for the future","volume":"119","author":"Robinson","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cmi.2022.10.030_bib2","doi-asserted-by":"crossref","first-page":"m3379","DOI":"10.1136\/bmj.m3379","article-title":"A\u00a0living WHO guideline on drugs for Covid-19","volume":"370","author":"Agarwal","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.cmi.2022.10.030_bib3","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.cmi.2022.05.005","article-title":"Immunocompromised patients have been neglected in COVID-19 trials: a call for action","volume":"28","author":"Tr\u00f8seid","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2022.10.030_bib4","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1001\/jama.2022.2274","article-title":"Estimates of SARS-CoV-2 omicron variant severity in Ontario, Canada","volume":"327","author":"Ulloa","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2022.10.030_bib5","article-title":"Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant","volume":"3","author":"Lyke","year":"2022","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.cmi.2022.10.030_bib6","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1182\/bloodadvances.2021006917","article-title":"Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients","volume":"6","author":"Haggenburg","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.cmi.2022.10.030_bib7","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/s41467-022-28578-0","article-title":"Humoral and cellular responses after a third dose of SARS-CoV-2 BNT162b2 vaccine in patients with lymphoid malignancies","volume":"13","author":"Re","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.cmi.2022.10.030_bib8","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41591-021-01355-0","article-title":"Delayed production of neutralizing antibodies correlates with fatal COVID-19","volume":"27","author":"Lucas","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.cmi.2022.10.030_bib9","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1016\/S2213-2600(20)30354-4","article-title":"SARS-CoV-2 viral load predicts COVID-19 mortality","volume":"8","author":"Pujadas","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.cmi.2022.10.030_bib10","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/bs.ircmb.2018.07.006","article-title":"T\u00a0lymphocytes as measurable targets of protection and vaccination against viral disorders","volume":"342","author":"Monette","year":"2019","journal-title":"Int Rev Cell Mol Biol"},{"key":"10.1016\/j.cmi.2022.10.030_bib11","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/s41591-021-01386-7","article-title":"CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer","volume":"27","author":"Bange","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.cmi.2022.10.030_bib12","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/S1470-2045(20)30442-3","article-title":"COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study","volume":"21","author":"Lee","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cmi.2022.10.030_bib13","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1093\/infdis\/jiaa311","article-title":"Decreased B cells on admission associated with prolonged viral RNA shedding from the respiratory tract in coronavirus disease 2019: a case-control study","volume":"222","author":"Hao","year":"2020","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cmi.2022.10.030_bib14","doi-asserted-by":"crossref","first-page":"e452","DOI":"10.1016\/j.clml.2021.12.011","article-title":"Thrombotic and clinical outcomes in patients with hematologic malignancy and COVID-19","volume":"22","author":"Cook","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.cmi.2022.10.030_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100775","article-title":"When hematologic malignancies meet COVID-19 in the United States: infections, death and disparities","volume":"47","author":"Wang","year":"2021","journal-title":"Blood Rev"},{"key":"10.1016\/j.cmi.2022.10.030_bib16","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1182\/bloodadvances.2021005691","article-title":"A\u00a0prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study","volume":"6","author":"Visco","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.cmi.2022.10.030_bib17","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1097\/HS9.0000000000000538","article-title":"Risk factors and mortality of COVID-19 in patients with lymphoma: a multicenter study","volume":"5","author":"Regalado-Artamendi","year":"2021","journal-title":"Hemasphere"},{"key":"10.1016\/j.cmi.2022.10.030_bib18","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/ajh.26209","article-title":"Prolonged in-hospital stay and higher mortality after Covid-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy","volume":"96","author":"Dul\u00e9ry","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.cmi.2022.10.030_bib19","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1182\/blood.2020008423","article-title":"Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19","volume":"136","author":"Hueso","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2022.10.030_bib20","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1182\/bloodadvances.2021005094","article-title":"Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma","volume":"5","author":"Perry","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.cmi.2022.10.030_bib21","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1111\/bjh.18029","article-title":"BNT162b2 mRNA COVID-19 vaccine booster induces seroconversion in patients with B-cell non-Hodgkin lymphoma who failed to respond to two prior vaccine doses","volume":"196","author":"Avivi","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cmi.2022.10.030_bib22","doi-asserted-by":"crossref","first-page":"e542","DOI":"10.1016\/S2352-3026(21)00199-X","article-title":"Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma","volume":"8","author":"Lim","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.cmi.2022.10.030_bib23","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/bjh.18149","article-title":"Rituximab-treated patients with lymphoma develop strong CD8 T-cell responses following COVID-19 vaccination","volume":"197","author":"Riise","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cmi.2022.10.030_bib24","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1038\/s41375-020-0959-x","article-title":"COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus","volume":"34","author":"Scarf\u00f2","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.cmi.2022.10.030_bib25","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1159\/000514071","article-title":"Immune dysfunction in patients with chronic lymphocytic leukemia and challenges during COVID-19 pandemic","volume":"144","author":"Langerbeins","year":"2021","journal-title":"Acta Haematol"},{"key":"10.1016\/j.cmi.2022.10.030_bib26","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1182\/blood.2020006965","article-title":"Outcomes of COVID-19 in patients with CLL: a multicenter international experience","volume":"136","author":"Mato","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2022.10.030_bib27","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/s41375-021-01424-w","article-title":"Covid-19 in patients with chronic lymphocytic leukemia: clinical outcome and B- and T-cell immunity during 13 months in consecutive patients","volume":"36","author":"Blixt","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.cmi.2022.10.030_bib28","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/ejh.13729","article-title":"mRNA COVID-19 vaccines in patients with chronic lymphocytic leukemia: a systematic review and meta-analysis","volume":"108","author":"Molica","year":"2022","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.cmi.2022.10.030_bib29","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1182\/bloodadvances.2021006633","article-title":"Cellular and humoral immune response to mRNA COVID-19 vaccination in subjects with chronic lymphocytic leukemia","volume":"6","author":"Lyski","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.cmi.2022.10.030_bib30","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41408-020-00372-5","article-title":"Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality","volume":"10","author":"Mart\u00ednez-L\u00f3pez","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.cmi.2022.10.030_bib31","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1182\/blood.2020008150","article-title":"Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set","volume":"136","author":"Chari","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2022.10.030_bib32","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/bjh.17937","article-title":"Key findings from the UKCCMP cohort of 877 patients with haematological malignancy and COVID-19: disease control as an important factor relative to recent chemotherapy or anti-CD20 therapy","volume":"196","author":"Booth","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cmi.2022.10.030_bib33","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/hon.2974","article-title":"Successful early use of anti-SARS-CoV-2 monoclonal neutralizing antibodies in SARS-CoV-2 infected hematological patients - a Czech multicenter experience","volume":"40","author":"Weinbergerov\u00e1","year":"2022","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.cmi.2022.10.030_bib34","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/bjh.18066","article-title":"Immune response to COVID-19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T cell response","volume":"197","author":"Ramasamy","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cmi.2022.10.030_bib35","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1200\/JCO.21.02257","article-title":"Determinants of neutralizing antibody response after SARS CoV-2 vaccination in patients with myeloma","volume":"40","author":"Nooka","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cmi.2022.10.030_bib36","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/bjh.17608","article-title":"Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma","volume":"195","author":"Avivi","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cmi.2022.10.030_bib37","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/s41409-019-0487-3","article-title":"Early and late hematologic toxicity following CD19 CAR-T cells","volume":"54","author":"Fried","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.cmi.2022.10.030_bib38","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1182\/bloodadvances.2021005616","article-title":"COVID-19 and CAR-T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP","volume":"6","author":"Busca","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.cmi.2022.10.030_bib39","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1038\/s41375-021-01466-0","volume":"35","author":"Spanjaart","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.cmi.2022.10.030_bib40","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/bloodadvances.2021006112","article-title":"Impaired immune response to COVID-19 vaccination in patients with B-cell malignancies after CD19 CAR T-cell therapy","volume":"6","author":"Dahiya","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.cmi.2022.10.030_bib41","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/bjh.17818","article-title":"Safety and antibody response after one and\/or two doses of BNT162b2 anti-SARS-CoV-2 mRNA vaccine in patients treated by CAR T cells therapy","volume":"196","author":"Gastinne","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cmi.2022.10.030_bib42","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ccell.2022.01.010","article-title":"Immune response to three doses of mRNA SARS-CoV-2 vaccines in CD19-targeted chimeric antigen receptor T cell immunotherapy recipients","volume":"40","author":"Sesques","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cmi.2022.10.030_bib43","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with Covid-19","volume":"384","author":"Horby","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2022.10.030_bib44","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s40560-021-00580-6","article-title":"Effects of dexamethasone on immune dysfunction and ventilator-associated pneumonia in COVID-19 acute respiratory distress syndrome: an observational study","volume":"9","author":"Cour","year":"2021","journal-title":"J\u00a0Intensive Care"},{"key":"10.1016\/j.cmi.2022.10.030_bib45","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/s41375-022-01511-6","article-title":"Convalescent plasma improves overall survival in patients with B-cell lymphoid malignancy and COVID-19: a longitudinal cohort and propensity score analysis","volume":"36","author":"Hueso","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.cmi.2022.10.030_bib46","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1182\/blood.2021011841","article-title":"COVID-19 in patients with CLL: iimproved survival outcomes and update on management strategies","volume":"138","author":"Roeker","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2022.10.030_bib47","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1001\/jamaoncol.2021.1799","article-title":"Association of convalescent plasma therapy with survival in patients with hematologic cancers and COVID-19","volume":"7","author":"Thompson","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.cmi.2022.10.030_bib48","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1001\/jama.2021.18178","article-title":"Effect of convalescent plasma on organ support-free days in critically ill patients with COVID-19: a randomized clinical trial","volume":"326","author":"Estcourt","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2022.10.030_bib49","author":"US Food and Drug Administration"},{"key":"10.1016\/j.cmi.2022.10.030_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.640093","article-title":"Two different antibody-dependent enhancement (ADE) risks for SARS-CoV-2 antibodies","volume":"12","author":"Ricke","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.cmi.2022.10.030_bib51","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/S0140-6736(21)00897-7","article-title":"Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial","volume":"397","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2022.10.030_bib52","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa2102685","article-title":"Bamlanivimab plus etesevimab in mild or moderate Covid-19","volume":"385","author":"Dougan","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2022.10.030_bib53","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1056\/NEJMoa2108163","article-title":"REGEN-COV antibody combination and outcomes in outpatients with Covid-19","volume":"385","author":"Weinreich","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2022.10.030_bib54","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa2107934","article-title":"Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab","volume":"385","author":"Gupta","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2022.10.030_bib55","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(22)00163-5","article-title":"RECOVERY Collaborative Group. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"399","author":"Abani","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2022.10.030_bib56","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1038\/s41591-022-01792-5","article-title":"Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies","volume":"28","author":"Bruel","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.cmi.2022.10.030_bib57","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abl8124","article-title":"The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans","volume":"14","author":"Loo","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.cmi.2022.10.030_bib58","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1001\/jama.2021.24931","article-title":"For pre-exposure prophylaxis of COVID-19","volume":"327","author":"Tixagevimab","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2022.10.030_bib59","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S2213-2600(22)00180-1","article-title":"Efficacy and safety of intramuscular administration of tixagevimab\u2013cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"10","author":"Montgomery","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.cmi.2022.10.030_bib60","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/S2213-2600(22)00215-6","article-title":"Tixagevimab\u2013cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial","volume":"10","author":"Ginde","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.cmi.2022.10.030_bib61","author":"US Food and Drug Administration"},{"key":"10.1016\/j.cmi.2022.10.030_bib62","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41586-022-04594-4","article-title":"Antibody evasion properties of SARS-CoV-2 Omicron sublineages","volume":"604","author":"Iketani","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.cmi.2022.10.030_bib63","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1056\/NEJMc2207519","article-title":"Efficacy of antibodies and antiviral drugs against omicron BA.2.12.1, BA.4, and BA.5 subvariants","volume":"387","author":"Takashita","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2022.10.030_bib64","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/s41586-022-04980-y","article-title":"BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection","volume":"608","author":"Cao","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.cmi.2022.10.030_bib65","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1473-3099(21)00485-0","article-title":"Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial","volume":"22","author":"Ader","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2022.10.030_bib66","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of covid-19 - final report","volume":"383","author":"Beigel","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2022.10.030_bib67","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1001\/jama.2020.16349","article-title":"Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial","volume":"324","author":"Spinner","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2022.10.030_bib68","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa2116846","article-title":"Early remdesivir to prevent progression to severe Covid-19 in outpatients","volume":"386","author":"Gottlieb","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2022.10.030_bib69","doi-asserted-by":"crossref","first-page":"o926","DOI":"10.1136\/bmj.o926","article-title":"Covid-19: what is the evidence for the antiviral molnupiravir?","volume":"377","author":"Extance","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.cmi.2022.10.030_bib70","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients","volume":"386","author":"Jayk Bernal","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2022.10.030_bib72","doi-asserted-by":"crossref","first-page":"e342","DOI":"10.1093\/cid\/ciac443","article-title":"Effectiveness of Paxlovid in reducing severe coronavirus disease 2019 and mortality in high-risk patients","volume":"76","author":"Najjar-Debbiny","year":"2023","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X22005444?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X22005444?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:33:23Z","timestamp":1761118403000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X22005444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":71,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S1198743X22005444"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2022.10.030","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"B-cell malignancies and COVID-19: a narrative review","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2022.10.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}